Aurinia Pharmaceuticals Inc. Share Price Toronto S.E.
Equities
AUP
CA05156V1022
Biotechnology & Medical Research
Sales 2024 * | 223M 305M 18.61B | Sales 2025 * | 288M 393M 23.98B | Capitalization | 710M 971M 59.2B |
---|---|---|---|---|---|
Net income 2024 * | -6M -8.2M -500M | Net income 2025 * | 58M 79.28M 4.84B | EV / Sales 2024 * | 1.64 x |
Net cash position 2024 * | 344M 470M 28.69B | Net cash position 2025 * | 390M 534M 32.56B | EV / Sales 2025 * | 1.11 x |
P/E ratio 2024 * |
-89.3
x | P/E ratio 2025 * |
12.4
x | Employees | 300 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.55% |
Latest transcript on Aurinia Pharmaceuticals Inc.
Managers | Title | Age | Since |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 16/93/16 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 29/19/29 |
Robert Foster
FOU | Founder | 65 | 16/93/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 16/93/16 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 26/19/26 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 29/19/29 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |